Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;41(4):663-673.
doi: 10.1002/hon.3174. Epub 2023 May 22.

Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data

Elif Birtas Atesoglu  1 , Zafer Gulbas  2 , Ant Uzay  3 , Muhit Ozcan  4 , Fahir Ozkalemkas  5 , Mehmet Sinan Dal  6 , Hakan Kalyon  1 , Olga Meltem Akay  1 , Burak Deveci  7 , Huseyin Bekoz  8 , Omur Gokmen Sevindik  8 , Tayfur Toptas  9 , Fergun Yilmaz  9 , Derya Koyun  4 , Nihan Alkis  10 , Inci Alacacioglu  11 , Mehmet Sonmez  12 , Irfan Yavasoglu  13 , Anil Tombak  14 , Ozgur Mehtap  15 , Fatih Kurnaz  16 , Orhan Kemal Yuce  17 , Volkan Karakus  18 , Mehmet Turgut  19 , Derya Deniz Kurekci  19 , Mesut Ayer  20 , Muzaffer Keklik  21 , Deram Buyuktas  22 , Murat Ozbalak  20 , Burhan Ferhanoglu  1
Affiliations

Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data

Elif Birtas Atesoglu et al. Hematol Oncol. 2023 Oct.

Abstract

Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion trial conducted in patients with relapsed/refractory (R/R) B-cell lymphoma. However, the real-world data of patients of all ages with no strict selection criteria are still lacking. Herein, this retrospective study aimed to evaluate the outcomes of diffuse large B-cell lymphoma (DLBCL) patients who received glofitamab via compassionate use in Turkey. Forty-three patients from 20 centers who received at least one dose of the treatment were included in this study. The median age was 54 years. The median number of previous therapies was 4, and 23 patients were refractory to first-line treatment. Twenty patients had previously undergone autologous stem cell transplantation. The median follow-up time was 5.7 months. In efficacy-evaluable patients, 21% and 16% of them achieved complete response and partial response, respectively. The median response duration was 6.3 months. The median progression-free survival (PFS) and overall survival (OS) was 3.3 and 8.8 months, respectively. None of the treatment-responsive patients progressed during the study period, and their estimated 1-year PFS and OS rate was 83%. The most frequently reported toxicity was hematological toxicity. Sixteen patients survived, while 27 died at the time of the analysis. The most common cause of death was disease progression. One patient died of cytokine release syndrome during the first cycle after receiving the first dose of glofitamab. Meanwhile, two patients died due to glofitamab-related febrile neutropenia. This is the largest real-world study on the effectiveness and toxicity of glofitamab treatment in R/R DLBCL patients. The median OS of 9 months seems promising in this heavily pretreated group. The toxicity related mortality rates were the primary concerns in this study.

Keywords: bispecific antibodies; glofitamab; relapsed/refractory diffuse large B-cell lymphoma.

PubMed Disclaimer

References

REFERENCES

    1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540-1545. https://doi.org/10.1056/nejm199512073332305
    1. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. https://doi.org/10.1182/blood-2017-03-769620
    1. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155-165. https://doi.org/10.1200/jco.19.00172
    1. Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, singlearm, phase 2 trial. Lancet Oncol. 2021;22(6):790-800. https://doi.org/10.1016/s1470-2045(21)00139-x
    1. Salles G, Duell J, Gonzalez Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective,single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978-988. https://doi.org/10.1016/s1470-2045(20)30225-4

LinkOut - more resources